Skip to content
Barrigel-HCP-Home-Hero-FLAT
Barrigel-HCP-Home-Hero-FLAT

Barrigel™ Rectal Spacer for Prostate Radiation Therapy

PHYSICIAN-CONTROLLED SPACING1-4

CONTROL
MATTERS

PLACEMENT YOU CAN PLAN ON1-5

Barrigel™ rectal spacer is the only sculptable spacer that gives you control over the shape and placement of the implant.1-4,6 Physician-controlled spacing provides confidence in achieving safe, symmetric and stable space.1-2**

036_100K_Website_Bug_600px

Quick Resources

Barrigel 2026 reimbursement guide thumbnail

Barrigel Reimbursement Guide

updated for 2026

See the Latest Guidelines
New Barrigel Patient Brochure 2026 thumbnail

Barrigel Patient Brochure

published January 2026

Download the Brochure
Barrigel prostate radiation guide thumbnail

Prostate Radiation Therapy Treatment Guide

with Barrigel Rectal Spacer

Get the Treatment Guide

DEMONSTRATED SAFETY1

BUILD STABLE
SPACE1-2,4

SAFETY MATTERS.

SAFETY MATTERS.

Barrigel Spacer delivers.1-2

Pivotal Trial Results1

Proven superior
in the reduction of acute grade 2+ GI toxicity compared to control

Zero
Barrigel spacer-related adverse events

3-Year Results
(ESTRO 2026 Abstract)7

Continued reduction
in long-term toxicities

Zero
long-term Grade 2+GI toxicities compared to control.

95.6%

ACHIEVE CONSISTENT COVERAGE2

SYMMETRY
MATTERS

Customize the implant with sculptable gel to ensure optimal coverage.1-2,4 In the Barrigel Pivotal Trial, 95.6% of implants were symmetric (centered on the midline.)2**
hcp-clinical-results--symmetry-barrigel-2

BUILD STABLE SPACE1-2,4

BUILD STABLE
SPACE1-2,4

Barrigel maintains stable rectal spacing during resorption.2† Even as Barrigel spacer gradually resorbs, shape and separation are maintained, on average, through 3 months.1-2 There were zero reports of implant migration in the Barrigel Pivotal Trial.2

IMMEDIATELY POST-INJECTION
hcp-home--stability-1b

Results may vary.

3 MONTHS POST-INJECTION
hcp-home--stability-2b

Results may vary.

References

  • **In a secondary analysis of data from the Barrigel pivotal trial, 95.6% of implants were found to be symmetric using the methodology from Fischer-Valuck BW et al. Pract Radiat Oncol (2017).

    †On average through 3 months

    1. Mariados NF, Orio PF III, King MT et al. JAMA Oncol (2023).‡§ 

    2. Svatos M, Chell E, King MT et al. Med Phys (2024).‡§ 

    3. Williams J, Mc Millan K, Chao M et al. J Med Imag Radiat Sci (2022).§

    4. Gejerman G, Goldstein MM, Chao M et al. Pract Radiat Oncol (2023).§ 

    5. King MT, Svatos M, Orio PF III et al. Pract Radiat Oncol (2023).‡§

    6. Data on file. As of 7/01/2025.

    7. King M, Chao M et al. Prospective Randomized Controlled Trial of Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: 3-Year Results. Presented at: European Society for Radiotherapy and Oncology 2026 Annual Congress; May 2026; Stockholm, Sweden. Proffered Paper 3623.‡§

    ‡ Study sponsored by Palette Life Sciences, now part of Teleflex.

    § One or more of the authors are paid consultants of Teleflex.

     

     

APMC088-01A
ANNOUNCEMENT:  Teleflex has entered into a definitive agreement to divest our Interventional Urology portfolio, including the UroLift System™, Barrigel™ rectal spacer, Deflux™ injectable gel, and Solesta™ bulking agent, to Intersurgical®. This transaction is expected to close in the second half of 2026, subject to customary regulatory approvals and other closing conditions.  We’re excited about this opportunity and remain committed to providing the same high-quality products, reliable service, and on-time delivery our customers expect. We will keep our physicians and patients informed throughout the transition. Please feel free to contact your sales representative with any questions or concerns.